The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | The impact of SF3B1 mutations in myelofibrosis
Jayastu Senapati, MBBS, MD, MD Anderson Cancer Center, Houston, TX, describes the findings of a study evaluating the impact of SF3B1 mutations in patients with myelofibrosis (MF). The study found that a higher proportion of patients carrying mutations in SF3B1 were transfusion-dependent and a lower proportion of these patients had grade 3 bone marrow fibrosis. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
